Vectura Group plc

Headquarters: Chippenham, United Kingdom

Founded: 1997

Employees: 450

show_chart LSE: VEC +0.12%

Market Cap

£1.00 Billion

GBP as of Oct. 1, 2021

US$1.36 Billion

history Market Cap History

Vectura Group plc market capitalization over time

Evolution of Vectura Group plc market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

history Market Cap History of Vectura Group plc

Detailed Description

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

Stocks & Indices

Vectura Group plc has the following listings and related stock indices.

Stock: LSE: VEC

Stock: FSX: V4TA


Key People

Bruno Angelici, Chairman Will Downie, (CEO)


Revenue: £190.6 million (2020)

Operating income: £132.8 million (2020)

Net income: £122.4 million (2020)



One Prospect West

Chippenham, SN14 6FH

United Kingdom

Phone: 44 1249 667700